



Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 1/17

Application Number
09/545,316

**FIG. 1****FIG. 2**

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 2/17

Application Number
09/545,316




FIG. 3




FIG. 4

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 3/17

Application Number
09/545,316




FIG. 4A

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 4/17

Application Number
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Discuss

Address: Back to Journalsoft Manuscript Management System

My JournalSoft

View Manuscripts

Personal Data

Preferences

MetaData

Help

Logout

Journalsoft

You are logged in with EDITOR privileges

MANUSCRIPTS TO REVIEW

You have completed 6 reviews. Thank you.
To view the reviews please click on the thumb icons.

99-121
Garcia, Isaac et al.
Influence of P21 immortalization of
Human Neuroblasts on P23-Dependent
Radiation Responses

99-127
Chen, Kevin et al.
The Apoptosome: Heart and Soul of the
Cell Death Machine

99-146
Grimbergen, J. D. et al.
The effect of cysteine in combination
with verapamil on the activity of ornithine
carboxylase of malignant cells in vitro

99-176
Pascalis, Paul et al.
The anticancer drug 5-fluorouracil
converts human malignant melanoma cells
to a pre-malignant state: Correlation with
alterations in the expression of the cyclin-
dependent kinase inhibitors

99-229
Huang, David et al.
Increased expression of the wild-type
p57 gene in melanoma metastases

YOUR COMPLETED REVIEWS

☐ = Suggest acceptance.
☐ = Suggest major or minor revisions.
☐ = Suggest rejection.

Your review received 4 days ago on 22-Jan-1999.
Other review received on 21-Jan-1999.
Declined publication on 21-Jan-1999

Your review received on 18-Jan-1999.
Other review received on 16-Jan-1999.
Accepted pending minor revision on 18-Jan-1999.
Revision due by 15-Feb-1999

Your review received on 24-Feb-1999.
Other review received on 24-Feb-1999.
Declined publication on 24-Feb-1999

Your review received on 01-Apr-1999.
Other review received on 01-Apr-1999.
Waiting for 12 months for publication (09/18/2001)
Revision due by 01-May-1999

Your review received on 10-Jun-1999.
Other review received on 08-Jun-1999.
Declined publication on 11-Jun-1999

Research Manuscripts Created

Internet

FIG. 4B

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 5/17

Application Number
09/545,316

Journalist Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail

Address Links

Martin Block Paper Sent: 11-Dec-1998 Review Due: 25-Dec-1998 Review Received: 22-Dec-1998

RECOMMENDATION

THIS REVIEW IS MARKED AS A DRAFT.
IT HAS NOT YET BEEN MADE AVAILABLE TO THE EDITORS AND AUTHORS.

RATINGS	Top 5%	Top 10%	Top 25%	Top 50%	Bottom 50%	No Comment
Scientific Quality	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Significance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Originality	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Clarity	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

COMMENTS TO THE AUTHORS

This study is a very nice experiment to validate the authors' hypothesis that radiosensitization FdUrd exposure depends on progression of cells through the S phase during drug exposure. Unfortunately the difference between the radiosensitization of the two E7-expressing clones and the parental cells is not as convincing as one would have liked. There also seem to be discrepancies between some of the reported data in the text and the tables (see below).

<U>Specific Comments</U>

1. Table I: The TS activity in the E7.9 clone during FdUrd exposure is much larger than that of the controls and is certainly not greater

THIS REVIEW IS CURRENTLY MARKED AS A DRAFT

Done

FIG. 4C

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 6/17

Application Number
09/545,316




FIG. 5




FIG. 6

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 7/17

Application Number
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail

Address Links

RATINGS	Top 5%	Top 10%	Top 25%	Top 50%	Bottom 50%	No Comment
Scientific Quality	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Significance	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Originality	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Clarity	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

COMMENTS TO THE AUTHORS

This study is a very nice experiment to validate the authors' hypothesis that radiosensitization FdUrd exposure depends on progression of cells through the S phase during drug exposure. Unfortunately the difference between the radiosensitization of the two E7-expressing clones and the parental cells is not as convincing as one would have liked. There also seem to be discrepancies between some of the reported data in the text and the tables (see below).

Specific Comments

1. Table I: The TS activity in the E7.9 clone during FdUrd exposure is much larger than that of the controls and is certainly not greater than 95% inhibited as indicated in the text (p. 8, par. 1).
2. Figure 1: Why are the data for only one experiment shown? It would seem to make more sense to show the data for all experiments with mean and standard errors for each point for the pooled data.

We are sorry that the reviewer seemed confused by this figure. In fact, it was a plot of mean values. We have added error bars and refined the caption to make this more clear.

3. P. 5, par. 3: The use of mean inactivation dose is perhaps the best way to analyze data fitted with the linear-quadratic model, but it is really an arcane method that will not be understood by 95% of the readers. If the authors have to use this method, they should indicate that the method heavily weights the initial part of the survival curve (for example, all data above 10% surviving fraction) and therefore, heavily weights the alpha component

Done

FIG. 5A

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 8/17

Application Number
09/545,316




FIG. 7




FIG. 8

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 9/17

Application Number
09/545,316




FIG. 9

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 10/17

Application Number
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Reload Home Search Favorites History Mail Print Edit

Address: http://www.journalsoft.com/

Journalsoft
To register for JournalSoft, please fill out the form.

Fill out the form below completely to register.

1. Your Login Information

Username
Please enter the username you would like to use to login to JournalSoft.

Password
Please enter a password that you can easily remember. Passwords are case-sensitive and should contain between 3 and 10 characters. The most secure passwords contain letters and numbers.
Please enter your favorite password:
Confirm password:
Please enter your main EMAIL address:

You may enter a clue to your password to help you remember it in the future:

Done Internet

FIG. 10

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 11/17

Application Number
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Exit

Address: Links

Journalsoft
To register for Journalsoft, please fill out the form.

Fill out the form below completely to register.

2. Enter your contact information below

Name:	<input type="text"/>		
Address:	<input type="text"/>		
City, State and Zip Code:	<input type="text"/>	<input type="text"/>	<input type="text"/>
Country:	<input type="text" value="- Select Continent -"/>		
Phone:	<input type="text"/>	(Not Required)	
Fax:	<input type="text"/>	(Not Required)	
Text Pager Email or Web Paging Address:	<input type="text"/>	(Not Required)	
If you have a Web Site, you can include your URL in the AD	Enter exactly as shown here: www.yourdomain.com DO NOT BEGIN YOUR ADDRESS WITH "http://"		

FIG. 11

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 12/17

Application Number
09/545,316

The screenshot shows a web browser window titled "Journalsoft Manuscript Management System - Microsoft Internet Explorer". The browser's address bar is empty, and the toolbar includes buttons for Back, Forward, Stop, Refresh, Home, Search, Favorites, History, Mail, Print, and Edit. The main content area displays a registration form for Journalsoft. On the left side of the form, there is a logo for "Journalsoft" and the text: "To register for JournalSoft, please fill out the form:". The main body of the form contains the following text: "Fill out the form below completely to register." followed by a section header "3. Please tell us about your research interests". Below this, it says: "In the space below please write a **SHORT NARRATIVE** about your research interests **OR** enter a list of **KEYWORDS** describing areas of research in which you are interested." This is followed by a paragraph: "This information will be used to help us assign appropriate reviewers for your submissions and to find papers that you may be interested in reviewing for *Neoplasia* should you agree to serve as a reviewer." Below this text is a large, empty rectangular text input area. At the bottom left of the form, there is a "Continue" button. The browser's status bar at the bottom shows "Done" and "Home" buttons.

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address Links

Journalsoft
To register for JournalSoft, please fill out the form:

Fill out the form below completely to register.

3. Please tell us about your research interests

In the space below please write a **SHORT NARRATIVE** about your research interests **OR** enter a list of **KEYWORDS** describing areas of research in which you are interested.

This information will be used to help us assign appropriate reviewers for your submissions and to find papers that you may be interested in reviewing for *Neoplasia* should you agree to serve as a reviewer.

Continue

Done Home

FIG. 12

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 13/17

Application Number
09/545,316

The screenshot shows a web browser window titled "Journalsoft Manuscript Management System - Microsoft Internet Explorer". The address bar shows "http://www.journalsoft.com/". The page content includes a sidebar with the "Journalsoft" logo and a registration instruction: "To register for JournalSoft, please fill out the form." The main content area has a heading "Fill out the form below completely to register." followed by a section titled "4. Collaborator Communities". This section explains that "Collaborator Communities" are groups of peers for proofing and revising manuscripts. It also states that members can view manuscript status, respond to reviews, and contribute to revisions. Below this text is a large empty text box for entering email addresses. At the bottom of the form area is a "Continue" button. The browser's status bar at the bottom shows "Done" and "Internet".

Journalsoft
To register for JournalSoft, please fill out the form.

Fill out the form below completely to register.

4. Collaborator Communities

"Collaborator Communities" are groups of your peers with whom you collaborate. JournalSoft provides tools for members of collaborator communities to proof and revise manuscripts on-line prior to submission. They also allow each co-author of a paper to view the manuscript's status in the peer-review process, to view and respond to reviews and editorial decisions, and to contribute to manuscript revisions.

To add people to your collaborator community, please enter their email addresses below. The members of your collaborator community will have access ONLY to those papers on which they are co-authors, or to those for which you explicitly give them permission to view.

Continue

FIG. 13

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 15/17

Application Number
09/545,316




FIG. 15

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 16/17

Application Number
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Discuss Realtime

Address Links

My JournalSoft

View Manuscripts

Personal Data

Preferences

MetaData

Help

Logout

Journalsoft

You are logged in with
EDITOR privileges

CONTRIBUTING AUTHORSHIP

You are the Corresponding Author for the following 2 manuscripts
To view or respond to reviews please click on the thumb icons

Corresponding Author	Contributing Authorship
<p>99-295</p> <p>Slegman, Lauren Daniel et al.</p> <p>Tasting Testing 455</p>	<p>Review 1 received 59 day(s) late on 25-Jan-2000</p> <p>Review 2 received 49 day(s) late on 17-Feb-2000</p> <p>Review 3 received 296 day(s) late on 03-Jul-1999</p>
<p>99-103</p> <p>Slegman, Lauren Daniel et al.</p> <p>Collateral Expression of Pro-angiogenic and Tumorigenic Properties in Intestinal Epithelial Cell Variants Selected for Resistance to Anoikis</p> <p>Research Article</p>	<p>Review 1 received 453 day(s) late on 21-Dec-1998</p> <p>Review 2 received 454 day(s) late on 30-Dec-1998</p>

Internet

Hierarchical Menu Trees Created

FIG. 16

Neoplasia Press, Inc.
Inventors: Ross, et al.

Page 17/17

Application Number
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Home Search Favorites History Mail Print Full Diskless Read from

Address: Back to Journalsoft Manuscript Management System

Links

My JournalSoft

View Manuscripts

Personal Data

Preferences

MetaData

Help

Logout

Journalsoft

You are logged in with **EDITOR** privileges

Hierarchical Menu Trees Created

CORRESPONDING AUTHOR

You are listed as an author of the following 2 manuscript(s).
To view or respond to reviews please click on the thumbnails

	CORRESPONDING AUTHOR	CONTRIBUTING AUTHOR
<p>1808086</p> <p>Humar, Ashay, et al</p> <p>Benfornisation Treating Page</p>	<p>Review 1 is 17 day(s) overdue</p> <p>The reviewer has been reminded to submit if promptly</p> <p>Review 2 We are searching for a second reviewer</p>	
<p>58-182</p> <p>Lawrence, Theodor S et al</p> <p>HPV16-E7 Expression Causes</p> <p>Fluorescein Uridine-Mediated</p> <p>Radicalization in SW620 Human Colon</p> <p>Carcinoma Cells</p> <p>Research Article</p>	<p>Review 1 received 459 day(s) late on 22-Dec-1998</p> <p>Review 2 received 453 day(s) late on 21-Dec-1998</p> <p>Accepted for publication (reviewed) 31-Dec-1998</p> <p>Reviews Due by 31-Jan-1999</p>	

Legend: = Suggest acceptance, = Suggest major or minor revisions, = Suggest rejection

Internet

FIG. 17